Addex Therapeutics reported robust anti-tussive activity for its novel GABAB positive allosteric modulator in a non-human primate chronic cough model. The result supports the asset's preclinical efficacy signal and is a constructive development for the company's pipeline. Market impact is likely limited unless followed by additional efficacy, safety, or clinical trial data.
Addex Therapeutics reported robust anti-tussive activity for its novel GABAB positive allosteric modulator in a non-human primate chronic cough model. The result supports the asset's preclinical efficacy signal and is a constructive development for the company's pipeline. Market impact is likely limited unless followed by additional efficacy, safety, or clinical trial data.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialOverall Sentiment
moderately positive
Sentiment Score
0.40
Ticker Sentiment
